FDD: Ocular Drug Delivery: Leveraging Your Assets from Other Therapeutic Areas
Wednesday, October 17 2012
8:00 am – 10:00 am
N/A (View All)
Location: MassBio, 300 Technology Square, 8th Floor, Cambridge, MA
Download full program (with abstracts & bios) here.
AGENDA:
There will be a panel discussion following the presentations with the participation of Kevin Bitterman, Principal at Polaris Ventures.
An Evolving Paradigm of Ocular Therapeutic Strategy and Delivery Technology Innovation
- Dr. Tina Guanting Qiu, Pharmaceutical Consultant Affiliate to Biologics Consulting Groups Inc., Council Member of Biomedical Council & Life Sciences at Gerson Lehman Group, MA
Cross Fertilization: Sustained Delivery and Nanotechnology in Ophthalmology
- Dr. Paul Ashton, CEO, pSivida Corp., Watertown, MA
Formulation for Target Organ-Specific Delivery: How to Improve a Drug’s Therapeutic Index and Generate IP to Protect the Investment
- Dr. William K. McVicar, CSO, Inotek Pharmaceuticals, Lexington, MA
The Advantages of Doctor Administered Treatments
- Dr. Michael Patane, CSO, EyeGate Pharma, Waltham, MA
Share MassBio
